NIH R01 · 2025
PROJECT SUMMARY Inadequate medication access and adherence causes poor health in the aging Medicare population—issues which are particularly salient among disadvantaged populations. The 340B Drug Pricing Program is an expansive, federal safety net program that intends to improve medication access and health outcomes for disadvantaged patients. It entitles qualifying hospitals or clinics to large manufacturer discounts when they purchase and dispense infused, injected, or oral outpatient drugs. The intent is for 340B hospitals to use savings to increase drug access and invest in services to improve outcomes for disadvantaged patients; however, there are no direct incentives nor oversight…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.